Verona Pharma Plc Stock Probability of Future Stock Price Finishing Over 42.43
| VRNA Stock | USD 39.45 0.75 1.87% |
Closest to current price Verona long CALL Option Payoff at Expiration
Verona |
Verona Pharma Target Price Odds to finish over 42.43
The tendency of Verona Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 42.43 or more in 90 days |
| 39.45 | 90 days | 42.43 | roughly 2.32 |
Based on a normal probability distribution, the odds of Verona Pharma to move over $ 42.43 or more in 90 days from now is roughly 2.32 (This Verona Pharma PLC probability density function shows the probability of Verona Stock to fall within a particular range of prices over 90 days) . Probability of Verona Pharma PLC price to stay between its current price of $ 39.45 and $ 42.43 at the end of the 90-day period is about 8.03 .
Given the investment horizon of 90 days Verona Pharma has a beta of 0.15. This entails as returns on the market go up, Verona Pharma average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Verona Pharma PLC will be expected to be much smaller as well. Additionally Verona Pharma PLC has an alpha of 0.56, implying that it can generate a 0.56 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Verona Pharma Price Density |
| Price |
Predictive Modules for Verona Pharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Verona Pharma PLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Verona Pharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Verona Pharma is not an exception. The market had few large corrections towards the Verona Pharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Verona Pharma PLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Verona Pharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | 0.15 | |
σ | Overall volatility | 4.08 | |
Ir | Information ratio | 0.16 |
Verona Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Verona Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Verona Pharma PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 458 K. Net Loss for the year was (54.58 M) with profit before overhead, payroll, taxes, and interest of 112 K. | |
| Verona Pharma PLC currently holds about 111.51 M in cash with (50.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance |
Verona Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Verona Stock often depends not only on the future outlook of the current and potential Verona Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Verona Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 79.3 M | |
| Cash And Short Term Investments | 271.8 M |
Verona Pharma Technical Analysis
Verona Pharma's future price can be derived by breaking down and analyzing its technical indicators over time. Verona Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Verona Pharma PLC. In general, you should focus on analyzing Verona Stock price patterns and their correlations with different microeconomic environments and drivers.
Verona Pharma Predictive Forecast Models
Verona Pharma's time-series forecasting models is one of many Verona Pharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Verona Pharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Verona Pharma PLC
Checking the ongoing alerts about Verona Pharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Verona Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| The company reported the previous year's revenue of 458 K. Net Loss for the year was (54.58 M) with profit before overhead, payroll, taxes, and interest of 112 K. | |
| Verona Pharma PLC currently holds about 111.51 M in cash with (50.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.83. | |
| Over 89.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from businesswire.com: Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance |
Check out Verona Pharma Backtesting, Verona Pharma Valuation, Verona Pharma Correlation, Verona Pharma Hype Analysis, Verona Pharma Volatility, Verona Pharma History as well as Verona Pharma Performance. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.